Structure

InChI Key OIGNJSKKLXVSLS-VWUMJDOOSA-N
Smile C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H28O5
Molecular Weight 360.45
AlogP 1.56
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 2.0
Polar Surface Area 94.83
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 26.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist PubMed PubMed
Primary Target
Glucocorticoid receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lupus Erythematosus, Systemic 4 D008180 ClinicalTrials
Tennis Elbow 4 D013716 ClinicalTrials
Spondylitis, Ankylosing 4 D013167 ClinicalTrials
Rhinitis, Allergic, Seasonal 4 D006255 ClinicalTrials
Arthritis, Psoriatic 4 D015535 ClinicalTrials
Hypereosinophilic Syndrome 3 D017681 ClinicalTrials
Spasms, Infantile 3 D013036 ClinicalTrials
Multiple Myeloma 3 D009101 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 3 D029424 ClinicalTrials
Biliary Atresia 3 D001656 ClinicalTrials
Cataract 3 D002386 ClinicalTrials
Glomerulonephritis, IGA 3 D005922 ClinicalTrials
Pulpitis 3 D011671 ClinicalTrials
Idiopathic Pulmonary Fibrosis 3 D054990 ClinicalTrials
Hepatitis, Alcoholic 3 D006519 ClinicalTrials
Pericarditis 3 D010493 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Kidney Diseases 3 D007674 ClinicalTrials
Hypersensitivity 3 D006967 ClinicalTrials
Lymphoma, Non-Hodgkin 3 D008228 ClinicalTrials
Purpura, Thrombocytopenic, Idiopathic 3 D016553 ClinicalTrials
Churg-Strauss Syndrome 3 D015267 ClinicalTrials
Croup 3 D003440 ClinicalTrials
Vestibular Neuronitis 3 D020338 ClinicalTrials
Anemia, Hemolytic, Autoimmune 3 D000744 ClinicalTrials
Eczema 3 D004485 ClinicalTrials
Headache 3 D006261 ClinicalTrials
Inflammation 3 D007249 ClinicalTrials
Glaucoma 3 D005901 ClinicalTrials
Glomerulonephritis, Membranous 3 D015433 ClinicalTrials
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 3 D056648 ClinicalTrials
Polymyalgia Rheumatica 3 D011111 ClinicalTrials
Abortion, Habitual 3 D000026 ClinicalTrials
Orbital Pseudotumor 3 D016727 ClinicalTrials
Leukemia, Biphenotypic, Acute 3 D015456 ClinicalTrials
Glaucoma, Open-Angle 3 D005902 ClinicalTrials
Graves Disease 3 D006111 ClinicalTrials
Ocular Hypertension 3 D009798 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Red-Cell Aplasia, Pure 3 D012010 ClinicalTrials
Glomerulonephritis 3 D005921 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Glomerulosclerosis, Focal Segmental 3 D005923 ClinicalTrials
Adrenal Insufficiency 3 D000309 ClinicalTrials
Pemphigus 3 D010392 ClinicalTrials
Eye Infections 3 D015817 ClinicalTrials
Sarcoma 3 D012509 ClinicalTrials
Ischemic Stroke 3 D000083242 ClinicalTrials
Endocardial Cushion Defects 3 D004694 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Mucocutaneous Lymph Node Syndrome 3 D009080 ClinicalTrials
Lupus Nephritis 3 D008181 ClinicalTrials
Diabetes Mellitus, Type 2 2 D003924 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Lichen Planus 2 D008010 ClinicalTrials
Muscular Dystrophy, Duchenne 2 D020388 ClinicalTrials
Giant Cell Arteritis 2 D013700 ClinicalTrials
Schizophrenia 2 D012559 ClinicalTrials
Renal Insufficiency, Chronic 2 D051436 ClinicalTrials
Granulomatosis with Polyangiitis 2 D014890 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Infertility 2 D007246 ClinicalTrials
Aspergillosis, Allergic Bronchopulmonary 2 D001229 ClinicalTrials
Immunoblastic Lymphadenopathy 2 D007119 ClinicalTrials
Colitis 2 D003092 ClinicalTrials
Lymphoma, T-Cell, Peripheral 2 D016411 ClinicalTrials
Microscopic Polyangiitis 2 D055953 ClinicalTrials
Pituitary ACTH Hypersecretion 2 D047748 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Alveolitis, Extrinsic Allergic 2 D000542 ClinicalTrials
Lymphoma, Large-Cell, Anaplastic 2 D017728 ClinicalTrials
Hemangioma 2 D006391 ClinicalTrials
Stomatitis, Aphthous 2 D013281 ClinicalTrials
Uveitis 2 D014605 ClinicalTrials
Hyperlipoproteinemia Type I 2 D008072 ClinicalTrials
Celiac Disease 2 D002446 ClinicalTrials
HIV Infections 2 D015658 ClinicalTrials
Scleroderma, Systemic 2 D012595 ClinicalTrials
Leprosy 2 D007918 ClinicalTrials
Pemphigoid, Benign Mucous Membrane 2 D010390 ClinicalTrials
Lipoma 1 D008067 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Lymphohistiocytosis, Hemophagocytic 1 D051359 ClinicalTrials
Canavan Disease 1 D017825 ClinicalTrials
Macular Degeneration 1 D008268 ClinicalTrials

Related Entries

MCS

Scaffolds

Salt
Salt
Salt
Salt
Mixture

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
10.62
General disorders and administration site conditions
10.4
Nervous system disorders
7.7
Respiratory, thoracic and mediastinal disorders
6.53
Gastrointestinal disorders
6.17
Vascular disorders
5.93
Musculoskeletal and connective tissue disorders
5.42
Skin and subcutaneous tissue disorders
4.71
Injury, poisoning and procedural complications
4.62
Psychiatric disorders
4.6
Metabolism and nutrition disorders
4.47
Blood and lymphatic system disorders
4.29
Investigations
3.5
Cardiac disorders
3.42
Renal and urinary disorders
3.13
Immune system disorders
3.07
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.32
Pregnancy, puerperium and perinatal conditions
2.17
Eye disorders
2.07

Cross References

Resources Reference
CAS NUMBER 50-24-8
ChEBI 8378
ChEMBL CHEMBL131
DrugBank DB00860
DrugCentral 2245
EPA CompTox DTXSID9021184
FDA SRS 9PHQ9Y1OLM
Human Metabolome Database HMDB0014998
Guide to Pharmacology 2866
KEGG C07369
PDB TUA
PharmGKB PA451096
PubChem 5755
SureChEMBL SCHEMBL3233
ZINC ZINC000003833821